The QT interval and the atypical antipsychotic, sertindole

References

• Wagstaff A J, Bryscm H M. Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995; 4: 370–400
   Web of Science ®Google Scholar
• Lamarque V. Clozapine associated-agranulocytosis: A review of the international experience. Encephale 1996; 22: 35–6
   PubMedGoogle Scholar
• Möller H J, Muller H, Borison R L, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a reevaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45–9
   PubMed Web of Science ®Google Scholar
• Tollefson G D, Sanger T M. Negative symptoms: a path-analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466–74
   PubMed Web of Science ®Google Scholar
• Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 207–13
   PubMed Web of Science ®Google Scholar
• Committee for Proprietary Medicinal Products. Note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia. CPMP/EWP/559/95. London 26 February, 1998
   Google Scholar
• Daniel D G, Wozniak P, Mack R J, et al. Long-term efficacy and safety comprison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group. Psychopharmacol Bull 1998; 34: 61–9
   PubMed Web of Science ®Google Scholar
• Tran P V, Hamilton S H, Kuntz A J, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18
   PubMed Web of Science ®Google Scholar
• Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 1997; 11: 65–71
   PubMed Web of Science ®Google Scholar
• Weaver M G. Olanzapine-pharmacology and clinical evaluation of a new atypical antipsychotic. J Serotonin Res 1997; 4: 145–57
   Google Scholar
• Tamminga C A, Mack R J, Granneman G R, et al. Sertindole in the treatment of psychosis in schizophrenia: Efficacy and safety. Int Clin Psychopharmacol 1997; 12: S29–S35
   PubMedGoogle Scholar
• van Kammen D P, McEvoy J P, Targum S D. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168–75
   PubMed Web of Science ®Google Scholar
• Zimbroff D L, Kane J M, Tamminga C A, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154: 782–91
   PubMed Web of Science ®Google Scholar
• Anon. Zum Risikoprofil von Sertindol (Serdolect). Arznei-Telegramm 1997; 10: 128
   Google Scholar
• Anon. Neue “atypische” Neuroleptika: Olanzapin (Zyprexa)/Sertindol (Serdolect). Arznei-Telegramm 1997; 10: 103–5
   Google Scholar
• Beasley C M, Tollefson G D, Tran P V, et al. Safety of olanzapine. J Clin Psychiatry 1997; 58: 13–17
   PubMed Web of Science ®Google Scholar
• Flugelman M Y, Tal A, Pollack S, et al. Psychotropic drugs and long QT syndromes: case reports. J Clin Psychiatry 1985; 46: 290–1
   PubMedGoogle Scholar
• Parsons M, Buckley N A. Overdose of antipsychotic drugs: practical management guidelines. CNS drugs 1997; 7: 427–41
   Google Scholar
• Buckley N A, Whyte I M, Dawson A H, et al. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33: 199–204
   PubMed Web of Science ®Google Scholar
• Kiriike N, Maeda Y, Nishiwaki S, et al. latrogenic torsade de pointes induced by thirodazine. Biol Psychiatry 1987; 22: 99–103
   PubMedGoogle Scholar
• Baker B, Dorian P, Sandor P, et al. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997; 17: 15–21
   PubMed Web of Science ®Google Scholar
• Guy S, Silke B. The electrocardiogram as a tool for therapeutic monitoring: A critical analysis. J Clin Psychiatry 1990; 51: 37–9
   PubMedGoogle Scholar
• Hewer W, Rost W, Gattaz F. Cardiovascular effects of fluvoxamine and maprotiline in depressed patients. Eur Arch Psychiatry Clin Neurosci 1995; 246: 1–6
   PubMedGoogle Scholar
• Kresse Hermsdorf M, Muller Oerlinghausen B. Tricyclic neuroleptic and antidepressant overdose: epidemiological, electrocardiographic, and clinical features-a survey of 92 cases. Pharmacopsychiatry 1990; (Suppl) 23: 17–22
   Google Scholar
• Van de Merwe T J, Silverstone T, Ankier S I. Electrophysiological and haemodynamic changes with trazodone, amitriptyline and placebo in depressed out-patients. Curr. Med Res Opin 1984; 9: 339–52
   PubMed Web of Science ®Google Scholar
• Di Salvo T G, O'Gara P T. Torsade de potates caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 1995; 18: 285–90
   PubMedGoogle Scholar
• Henderson R A, Lane S, Henry J A. Life-threatening ventricular arrhythmia (torsade de pointes) after haloperidol overdose. Hum Exp Toxicol 1991; 10: 59–62
   PubMed Web of Science ®Google Scholar
• Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 1997; 157: 2013–5
   PubMed Web of Science ®Google Scholar
• Kriwisky M, Perry G Y, Tarchitsky D, et al. Haloperidol-induced torsade de pointes. Chest 1990; 98: 482–4
   PubMed Web of Science ®Google Scholar
• Lawrence K R, Nasraway S A. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997; 17: 531–7
   PubMed Web of Science ®Google Scholar
• Metzger E, Friedman R. Prolongation of die corrected QT and torsade de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993; 13: 128–32
   PubMed Web of Science ®Google Scholar
• Fulop G, Phillips R A, Shapiro A K. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987; 144: 673–5
   PubMed Web of Science ®Google Scholar
• Ravin D S, Levenson J W. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997; 31: 867–70
   PubMed Web of Science ®Google Scholar
• Suessbrich H, Schonherr R, Heinemann S H, et al. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997; 120: 968–74
   PubMed Web of Science ®Google Scholar
• Franz M R. Time for yet another QT correction algorithm? Bazett and beyond. J Am Coll Cardiol 1994; 23: 1554–6
   PubMedGoogle Scholar
• Garson A J. How to measure the QT internal-what is normal?. Am J Cardiol 1993; 72: 14B–16B
   Web of Science ®Google Scholar
• Karjalainen J, Viitasalo M, Manttari M, et al. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 1994; 23: 1547–53
   PubMed Web of Science ®Google Scholar
• Higham P D, Campbell R WF. QT dispersion. Br Heart J 1994; 71: 508–10
   PubMedGoogle Scholar
• Doig J. Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug Safety 1995; 17: 265–75
   Google Scholar
• Drici M D, Wang W X, Woosley R L. Comparison of risperidone, olanzapine and sertindole on QT interval in isolated feline hearts. Presented at 35th Annual American College of Neuropsychopharmacology Meeting, Puerto Rico, 1996. Abstract book, 7–13 December, 1996; 265
   Google Scholar
• Bamett A A. Safety concerns over antipsychotic drug, sertindole. Lancet 1997; 348: 256
   Google Scholar
• Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57: 12–25
   PubMed Web of Science ®Google Scholar